Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $125.63 +0.88%
EPS Growth %: +32.6%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +32.6%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.27, $0.31 better than the analyst estimate of $0.96. Revenue for the quarter came in at $290 million versus the consensus estimate of $251.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $4.00-$4.20, versus the consensus of $3.96. Halozyme Therapeutics sees FY2024 revenue of $900-1020 million, versus the consensus of $983.9 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Zefiro Methane closes C$5M non-brokered private placement
- Goldcana closes $1M private placement of flow-through shares
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
